Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.

Nallamothu, Brahmajee K

Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. [electronic resource] - European heart journal Aug 2005 - 1506-12 p. digital

Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0195-668X

10.1093/eurheartj/ehi181 doi


Abciximab
Adult
Aged
Angina Pectoris--drug therapy
Antibodies, Monoclonal--administration & dosage
Anticoagulants--administration & dosage
Bundle-Branch Block--drug therapy
Coronary Restenosis--etiology
Coronary Stenosis--drug therapy
Drug Therapy, Combination
Female
Fibrinolytic Agents--administration & dosage
Hemorrhage--chemically induced
Humans
Immunoglobulin Fab Fragments--administration & dosage
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction--etiology
Partial Thromboplastin Time--mortality
Recombinant Proteins--administration & dosage
Recurrence
Regression Analysis
Survival Analysis
Tissue Plasminogen Activator--administration & dosage
Treatment Outcome